EPISODE · Mar 27, 2026 · 5 MIN
Cagri Sema Next Generation Drug Update
from Livingdiabetes
In this episode, we look at CagriSema, a next-generation combination medication that pairs semaglutide with cagrilintide, an amylin analogue. We explain how this dual-pathway approach works, review the impressive phase three clinical trial results showing A1C reductions exceeding two percentage points and weight loss of fifteen to twenty percent, discuss the side effect profile, and explore when this medication might become available. Follow us on social media for updates and more content.
What this episode covers
In this episode, we look at CagriSema, a next-generation combination medication that pairs semaglutide with cagrilintide, an amylin analogue. We explain how this dual-pathway approach works, review the impressive phase three clinical trial results showing A1C reductions exceeding two percentage points and weight loss of fifteen to twenty percent, discuss the side effect profile, and explore when this medication might become available. Follow us on social media for updates and more content.
NOW PLAYING
Cagri Sema Next Generation Drug Update
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.